Menu
Currency
GWAS Study

Ancestry and Genetic Associations with Bronchopulmonary Dysplasia in Preterm Infants.

Torgerson DG, Ballard PL, Keller RL et al.

30113228 PubMed ID
GWAS Study Type
352 Participants
53 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

TD
Torgerson DG
BP
Ballard PL
KR
Keller RL
OS
Oh SS
HS
Huntsman S
HD
Hu D
EC
Eng C
BE
Burchard EG
BR
Ballard RA
Chapter II

Abstract

Summary of the research findings

Bronchopulmonary dysplasia in premature infants is a common and often severe lung disease with long-term sequelae. A genetic component is suspected but not fully defined. We performed an ancestry and genome-wide association study to identify variants, genes, and pathways associated with survival without bronchopulmonary dysplasia in 387 high-risk infants treated with inhaled nitric oxide in the Trial of Late Surfactant study. Global African genetic ancestry was associated with increased survival without bronchopulmonary dysplasia among infants of maternal self-reported Hispanic white race/ethnicity [odds ratio (OR) = 4.5, P = 0.01]. Admixture mapping found suggestive outcome associations with local African ancestry at chromosome bands 18q21 and 10q22 among infants of maternal self-reported African-American race/ethnicity. For all infants, the top individual variant identified was within the intron of NBL1, which is expressed in midtrimester lung and is an antagonist of bone morphogenetic proteins ( rs372271081 , OR = 0.17, P = 7.4 × 10-7). The protective allele of this variant was significantly associated with lower nitric oxide metabolites in the urine of non-Hispanic white infants ( P = 0.006), supporting a role in the racial differential response to nitric oxide. Interrogating genes upregulated in bronchopulmonary dysplasia lungs indicated association with variants in CCL18, a cytokine associated with fibrosis and interstitial lung disease, and pathway analyses implicated variation in genes involved in immune/inflammatory processes in response to infection and mechanical ventilation. Our results suggest that genetic variation related to lung development, drug metabolism, and immune response contribute to individual and racial/ethnic differences in respiratory outcomes following inhaled nitric oxide treatment of high-risk premature infants.

136 European ancestry cases, 82 African American cases, 28 Hispanic cases, 41 European ancestry controls, 51 African American controls, 14 Hispanic controls

Chapter III

Study Statistics

Key metrics and study information

352
Total Participants
GWAS
Study Type
No
Replicated
Hispanic or Latin American, European, African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.